Future of Digital Health in Drug Development

Evinova and Merck KGaA Partner on AI Clinical Trials

New strategic collaboration aims to accelerate drug R&D using an AI-native platform to optimize study designs.

By Avantgarde News Desk·July 29, 2026·1 min read

A modern laboratory with digital data overlays on glass screens, showing 3D molecular structures and clinical trial statistics.
Photo: Avantgarde News

Evinova and Merck KGaA announced a strategic partnership on July 28, 2026, to launch an AI-native clinical development platform ^[1]. The collaboration aims to accelerate global drug research and development by optimizing study designs ^[2]. This technology focuses on reducing operational bottlenecks that often delay clinical trials ^[1].

Merck KGaA will deploy these AI tools to streamline its development pipeline and enhance efficiency ^[1]. The platform provides data-driven insights to help researchers make faster decisions during the trial process ^[2]. Both companies expect the partnership to set new standards for digital health in the pharmaceutical industry ^[1].

Editorial notes

Transparency note

AI assisted drafting. Human edited and reviewed.

AI assisted: Yes
Human review: Yes
Last updated: July 29, 2026

Risk assessment

High

The report is based on two primary source URLs instead of the recommended minimum of three independent domains.

Sources

1.
Business Wire
Evinova and Merck KGaA Launch AI-Native Clinical Development Partnership
↗
Evinova announced a strategic collaboration with Merck KGaA to deploy an AI-native platform aimed at accelerating global clinical development, optimizing study designs, and reducing operational bottlenecks in drug R&D.
Back to reference